Treatment of disease responsive to modulation of cannabanoid 1(CB1) receptor signaling
US11566069B2 · kind B2 · utility
1Cited by
12References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 25, 2019 |
| Grant date | Jan 31, 2023 |
| Priority date | — |
| Expiry date | Jan 25, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel antibodies and fragments thereof that binds cannabinoid 1 (CB1) receptor. The antibodies and fragments thereof as disclosed herein include humanized antibodies that bind CB1 receptor. The invention also includes uses of the antibodies for treating a disease or disorder responsive to antagonism or agonism of the CB1 receptor.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.